New inhaled COVID-19 vaccine by McMaster enters phase-2 trials in Canada. The vaccine aims to provide stronger, needle-free ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

On a basic level, companies able to offer an alternative form of vaccine delivery to traditional options can set themselves apart from competitors. Needle phobia is a well-known problem ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. The ...

PharmaJet Tropis Needle-free Delivery System used to immunize an additional 1.5 million children in latest WHO campaign to ...

The presentation, entitled Intradermal needle-free vaccine delivery to reduce Ethiopia’s immunization costs and improve coverage, will be presented by Paul LaBarre, Vice President Global ...

US-based PharmaJet, a company dedicated to enhancing injectable performance through needle-free injection technology, has ...

McMaster University has developed an inhaled COVID-19 vaccine and studies are starting phase-two of human trials.

But some patients are afraid of the needle. Exploring alternative vaccine delivery systems could increase accessibility and encourage those who fear needles to receive necessary healthcare. While ...